Intellia Therapeutics Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z October 27, 2025 8:30 AM EDT Company Participants Jason Fredette John Leonard - President, CEO & Director David Lebwohl - Executive VP & Chief Medical Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Lili Nsongo - Leerink Partners LLC, Research Division Joseph Thome - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division William Pickering - Sanford C. Bernstein & Co., LLC.
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concerns in ATTR-CM seemed to be resolved quickly, and robust patient demand in pivotal trials support confidence in upcoming Phase 3 data and commercial launches. Cash runway extends into late 2026, but pivotal 2025 catalysts and potential blockbuster approval in multi-billion dollar markets could drive significant upside.
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief Medical Officer Edward J. Dulac - Executive Vice President, Chief Financial Officer and Treasurer John M.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
Investors often react fast to news. We see it with earnings announcements. And in biotech/pharma, we see it in response to news about drug trials. We saw that in spades on 5/29/25 for gene editor Intellia Therapeutics. The stock lost 29% after news of a “safety concern” surfaced during a Phase III drug trial. The news looked terrible. A lab test showed indications that a patient was experiencing an emergency liver problem. But the asymptomatic condition quickly corrected on its own.
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
